S. Reade

Phase I trial involving the pharmacodynamic (PD) study of circulating tumour cells, of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), with docetaxel (D) in patients (p) with advanced cancer.

J. Spicer, A. Gualberto, J. D. de Bono, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours

I. Judson, S. Kaye, C. Twelves, 2004, British Journal of Cancer.

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

J. Verweij, P. Workman, I. Judson, 2009, Molecular Cancer Therapeutics.

Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.

Andreas Schätzlein, Chris Twelves, Carol McCormick, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours

J. Verweij, I. Judson, S. Kaye, 2004, British Journal of Cancer.

A phase Ib study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors

J. Verweij, J. Bono, L. Pronk, 2005 .

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours.

P. Harris, S. Reade, Alison Reid, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.